Risk of ovarian cancer, even in women who have had a hysterectomy, increases with use of estrogen but not estrogen-progestin, according to results of a study reported in the July 17 issue of The Journal of the American Medical Association.
“For a short time, estrogen replacement was viewed as the perfect solution for many health problems in postmenopausal women,” Kenneth L. Noller, MD, from Tufts University in Boston, Massachusetts writes in an accompanying editorial.
“While the data from these observational studies do not establish causality, the association between estrogen use and ovarian cancer should be worrisome enough for clinicians to consider carefully whether to suggest [estrogen-replacement therapy (ERT)].”
In this follow-up study of 44,241 former participants in the Breast Cancer Detection Demonstration Project, James V. Lacey Jr., PhD, and colleagues from the National Cancer Institute in Bethesda, Maryland, interviewed postmenopausal subjects about use of ERT or estrogen-progestin replacement therapy (EPRT), other possible risk factors for ovarian cancer, and diagnosis of ovarian cancer, which was confirmed by medical records, death certificates, and state cancer registry data. Mean age at first follow-up was 56.6 years. All women had at least one ovary, although some had undergone hysterectomy.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!